WS #16120
Corporate restructuring is a key theme, with DXC Technology in advanced talks to sell its insurance software division for $2.4 billion to Eldridge, signaling a continued retreat from legacy IT services. In the biotech sector, EyePoint Pharmaceuticals is making a drastic pivot, cutting 53% of its workforce and halting wet AMD trials after a Phase 3 failure, refocusing entirely on diabetic macular edema. These moves highlight a market environment where companies are aggressively streamlining operations to focus on core competencies and high-growth areas, often at the cost of short-term stability.
Corporate Restructuring and M&A
Corporate restructuring is a key theme, with DXC Technology in advanced talks to sell its insurance software division for $2.4 billion to Eldridge, signaling a continued retreat from legacy IT services. In the biotech sector, EyePoint Pharmaceuticals is making a drastic pivot, cutting 53% of its workforce and halting wet AMD trials after a Phase 3 failure, refocusing entirely on diabetic macular edema. These moves highlight a market environment where companies are aggressively streamlining operations to focus on core competencies and high-growth areas, often at the cost of short-term stability.